From personal experience working with patients managing type 2 diabetes, I have observed that weight loss can often be more challenging compared to individuals without diabetes. This is primarily due to increased insulin resistance and the presence of metabolic syndrome, which creates a physiological environment where the body more fiercely resists losing fat. Medications such as semaglutide and tirzepatide have revolutionized diabetes and weight management treatments by mimicking hormones that regulate appetite and glucose control. However, as highlighted in the STEP and SURMOUNT clinical trials, individuals with type 2 diabetes tend to lose slightly less weight — approximately 3 to 6% less— compared to those without diabetes, even on the same medication doses. One reason for this difference is that people with diabetes often take other weight-promoting drugs, including certain types of insulin, which can counteract weight loss efforts. Additionally, the chronic inflammatory state and hormonal imbalances associated with metabolic syndrome complicate metabolic rates and fat loss. I advise patients to maintain realistic expectations and understand that weight loss in diabetes requires a holistic approach. Combining medication with tailored nutrition, consistent physical activity, and regular monitoring often yields the best results. In fact, slow and steady weight loss is still beneficial and significantly reduces cardiovascular risks and improves glycemic control. Therefore, while medications like semaglutide at a 2.4 mg dose and tirzepatide show promising outcomes, it is essential to manage other factors like insulin resistance and concurrent medications to maximize their effectiveness for weight loss in type 2 diabetes.